.-online.com antibodies

Datasheet for ABIN7515694 anti-CD22 (Epratuzumab Biosimilar) antibody



Overview

0.00.000	
Quantity:	200 µg
Target:	CD22 (Epratuzumab Biosimilar)
Reactivity:	Human
Host:	Humanized
Clonality:	Monoclonal
Conjugate:	This CD22 (Epratuzumab Biosimilar) antibody is un-conjugated
Application:	Flow Cytometry (FACS)
Product Details	
Purpose:	Humanized recombinant monoclonal antibody raised against human CD22.
Immunogen:	Original antibody is raised against by the humanization of LL2, a murine anti-CD22 IgG2a raised against Raji Burkitt lymphoma cells. Murine sequences comprise 5-10% of the molecule, with the remainder being human framework sequences, which greatly reduces
Clone:	HL22
Isotype:	lgG1
Specificity:	This antibody was prepared by the humanization of LL2, a murine anti-CD22 IgG2a raised against Raji Burkitt lymphoma cells. Murine sequences comprise 5-10 % of the molecule, with the remainder being human framework sequences, which greatly reduces the potential for immunogenicity.
Cross-Reactivity:	Human

Order at www.antibodies-online.com | www.antikoerper-online.de | www.anticorps-enligne.fr | www.antibodies-online.cn International: +49 (0)241 95 163 153 | USA & Canada: +1 877 302 8632 | support@antibodies-online.com Page 1/2 | Product datasheet for ABIN7515694 | 02/08/2024 | Copyright antibodies-online. All rights reserved.

Target Details	
Target:	CD22 (Epratuzumab Biosimilar)
Abstract:	CD22 (Epratuzumab Biosimilar) Products
Target Type:	Biosimilar
Background:	CD22 Molecule
Gene ID:	933
Application Details	
Application Notes:	Flow cytometry, The optimal working dilution should be determined by the end user.
Restrictions:	For Research Use only
Handling	
Format:	Liquid
Buffer:	In PBS with 0.02 % Proclin 300.
Preservative:	ProClin
Precaution of Use:	This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage:	4 °C,-20 °C
Storage Comment:	Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.